Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Cell-Permeable Peptide Inhibitor
CNI103 is a potent and metabolically stable cell-permeable peptide inhibitor of calcineurin. By selectively inhibiting the interaction between calcineurin and NFATc3, with a binding affinity of KD=16 nM, CNI103 effectively prevents NFATc3 activation both in vitro and in vivo. This reagent is valuable for investigating mechanisms involved in acute respiratory distress syndrome (ARDS) and other inflammatory diseases. -
PACE4 Inhibitor
Multi-Leu peptide is a potent inhibitor of the proprotein convertase PACE4, exhibiting a Ki value of 22 nM. This peptide competitively binds to the active site of PACE4, mimicking its substrate sequence and effectively blocking its catalytic activity. Multi-Leu peptide is valuable for elucidating the role of PACE4 in various biological processes, including its involvement in the progression of prostate cancer. -
CaMKII Inhibitor
Autocamtide-2-related inhibitory peptide is a selective inhibitor of Calcium/Calmodulin-dependent protein kinase II (CaMKII), exhibiting an IC50 value of 40 nM. This peptide effectively modulates CaMKII activity, making it a valuable tool for studying calcium signaling pathways and their implications in various physiological and pathological processes. Its high specificity and potency simplify the investigation of CaMKII-related mechanisms in cellular signaling research. -
Drp1-Fis1 Inhibitor
P110 heptapeptide is an inhibitor of the Drp1-Fis1 interaction, targeting mitochondrial dynamics to modulate cellular functions. This peptide exhibits anti-inflammatory, immunomodulatory, and neuroprotective properties, making it advantageous in research focused on neurodegenerative disorders, ischemic injury, and sepsis. P110 heptapeptide effectively reduces pathological actions linked to Drp1 without interfering with its essential physiological roles, providing a valuable tool for studying neurological and inflammatory diseases. -
MLCK Inhibitor
MLCK Inhibitor Peptide 18 is a selective inhibitor of myosin light chain kinase (MLCK) with an IC50 of 50 nM. This peptide demonstrates significant inhibition of MLCK activity while exhibiting minimal effects on Ca2+/calmodulin-dependent protein kinase II, requiring concentrations approximately 4000-fold higher for inhibition. This specificity makes it valuable for studying MLCK-related signaling pathways and cellular processes involving muscle contraction and cellular motility. -
CaMKII Inhibitor
Autocamtide-2-related inhibitory peptide, myristoylated is a potent and selective inhibitor of CaMKII, exhibiting an IC50 of 40 nM. This peptide is used in research applications to investigate the regulatory mechanisms of calcium-dependent signaling pathways. Its myristoylation enhances its membrane permeability, facilitating in vivo studies of CaMKII activity and function in various cellular contexts. -
Epidermal Cell Proliferation Inhibitor
Epidermal mitosis inhibiting pentapeptide primarily functions as an inhibitor of epidermal cell proliferation. This pentapeptide significantly reduces the DNA synthesis and mitotic rates of epidermal keratinocytes, making it a valuable tool in the study of skin cell dynamics. While it may moderately increase the incidence of skin tumors in cancer models, it also demonstrates a heightened capacity to promote regression of established tumors. Additionally, this compound is hydrolyzed by angiotensin-converting enzyme (ACE), further broadening its utility in cancer research applications. -
Holliday Linker Inhibitory Peptide
KWWCRW is a Holliday linker inhibitory peptide that targets homologous recombination repair (HDR) in DNA repair mechanisms. By binding to the reactive Holliday linker intermediate, KWWCRW prevents its degradation, thereby inhibiting HDR and site-specific recombination by bacteriophage in vitro. This peptide is valuable in cancer research, particularly in studying DNA repair pathways and potential therapeutic interventions. -
Chk Kinase Inhibitor
CBP501 Affinity Peptide is a Chk kinase inhibitor that effectively disrupts G2 cell cycle arrest triggered by DNA-damaging agents. This reagent is valuable for cancer research, enabling studies on cell cycle regulation and therapeutic responses to genotoxic stress. Its application can facilitate the investigation of DNA damage repair pathways and their implications in oncogenesis. -
p38 MAPK Inhibitor, JNK Inhibitor
HE4-1 leech peptide is a selective inhibitor of p38 MAPK and c-Jun N-terminal kinase (JNK). It effectively suppresses macrophage migration while maintaining normal macrophage immunological functions, such as phagocytosis, lysozyme activity, and the expression of various inflammatory factors. This peptide is primarily utilized in research focused on atherosclerosis and inflammation-related studies. -
ACE Inhibitory Peptide
Ser-Ala-Pro is an angiotensin-converting enzyme (ACE) inhibitory peptide characterized by an X-Pro structure. This compound exhibits significant potential in the study of hypertension, facilitating research into blood pressure regulation and cardiovascular health. Its mechanism of action makes it a valuable tool for exploring ACE-related pathways in various biological settings. -
TRAF6-p62 Inhibitor
TRAF6 peptide is a selective inhibitor of the TRAF6-p62 interaction. It effectively disrupts the ubiquitination of TrkA in NGF-dependent signaling pathways. This peptide demonstrates significant potential for research in neurological disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, epilepsy, and stroke. -
Bacterial Inhibitor
Targeting the bacterial sliding clamp peptide 46 is a short peptide designed to inhibit the bacterial sliding clamp (SC). By interfering with SC-dependent DNA synthesis, this peptide serves as a valuable tool for studying bacterial replication mechanisms and developing novel antibacterial strategies. Its application in research underscores its potential utility in exploring bacterial growth and resistance pathways. -
PACE4 Inhibitor
PACE4 Inhibitory Peptide C23 (Ac-(DLeu)LLLRVK-Amba) is a potent peptidomimetic compound that selectively inhibits the proprotein convertase PACE4. This peptide demonstrates significant antiproliferative effects on prostate cancer cell lines with a Ki value of 5 nM and IC50 values of 25 μM and 40 μM for DU145 and LNCaP cells, respectively. Additionally, PACE4 Inhibitory Peptide C23 is effective in suppressing tumor growth in vivo in LNCaP xenograft mouse models, making it a valuable tool for research in cancer biology and therapeutic development. -
PKC Pseudosubstrate Inhibitor
Protein Kinase C (19-35) Peptide serves as a pseudosubstrate inhibitor of Protein Kinase C (PKC). By potentially blocking the substrate-binding site within the kinase domain, this peptide renders the cytoplasmic form of PKC inactive. This inhibition is valuable for investigating PKC-related signaling pathways and understanding its role in various cellular processes. Its applications extend to research focused on cell proliferation, differentiation, and apoptosis associated with PKC activity. -
Inhibitor Peptide
pep2-EVKI (YNVYGIEEVKI) is an inhibitor peptide that selectively targets and disrupts the interactions of Protein Interacting with C kinase 1 (PICK1). This compound is known to exert opposing effects on synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) function relative to PICK1 expression. It serves as a valuable tool for studying synaptic signaling pathways and understanding the role of PICK1 in synaptic plasticity and related neurobiological processes. -
PKC Inhibitor
[Ala107]MBP(104-118) is a noncompetitive inhibitor of protein kinase C (PKC), exhibiting IC50 values between 46-145 μM. This peptide is utilized in research to study PKC activity and its role in cellular signaling pathways. Its ability to selectively inhibit PKC makes it a valuable tool in investigating the implications of PKC in various disease states and pharmacological interventions. -
PKC Inhibitor
N-Myristoyl-Lys-Arg-Thr-Leu-Arg is a selective inhibitor of protein kinase C (PKC), exhibiting an IC50 of 75 μM. This compound effectively inhibits the induction of the IL-2 receptor and production of IL-2 in the Jurkat human leukemic cell line. It can be utilized in research focused on understanding PKC-related signaling pathways and their role in immune responses. -
PKCβII Inhibitor
PKCβII Peptide Inhibitor I is a selective inhibitor of Protein Kinase C beta II (PKCβII). This peptide demonstrates significant cardioprotective effects in rat models of ischemia/reperfusion injury, making it a valuable tool in cardiovascular research. Additionally, it has been shown to prevent vascular endothelial dysfunction, highlighting its potential applications in studying vascular health and related pathologies. -
CDK2 Inhibitor
Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG) is a specific inhibitor of cyclin-dependent kinase 2 (CDK2). It has demonstrated the ability to induce apoptosis in U2OS osteosarcoma cells in a dose-dependent manner, making it a valuable tool for studying CDK2-mediated cell cycle regulation. This peptide is suitable for research applications aimed at understanding the role of CDK2 in cancer biology and potential therapeutic interventions. -
CDK2 Inhibitor
Cdk2/Cyclin Inhibitory Peptide II is a specific inhibitor of cyclin-dependent kinase 2 (CDK2), primarily influencing cell cycle regulation. This peptide has demonstrated the ability to induce apoptosis in U2OS osteosarcoma cells in a dose-dependent manner. Its application in research includes investigations into cell cycle dynamics and therapeutic strategies for cancer treatment. -
MDM2/p53 Inhibitor
Phage-derived 12/1 peptide is a potent inhibitor of the MDM2/p53 interaction, effectively disrupting the binding between MDM2 and p53, as well as MDMX and p53. This peptide demonstrates significant antitumor activity, exhibiting IC50 values of 0.15 μM for MDM2 and 1.25 μM for MDMX. It serves as a valuable tool for research investigating the modulation of p53 activity and the therapeutic potential in targeting MDM2/MDMX pathways in cancer. -
Virus Replication Inhibitor
Fusion Inhibitory Peptide (Z-D-Phe-Phe-Gly-OH) is a potent inhibitor of viral replication, targeting and disrupting the membrane fusion activity of viral glycoproteins. This compound is essential for studying viral pathogenesis and developing antiviral therapies, as it effectively impedes the entry of viruses into host cells. Its applications extend to research focused on the mechanisms of viral infections and the exploration of therapeutic strategies to prevent viral replication. -
HIV Inhibitor
(D-Ala)-Peptide T is an octapeptide that acts as an HIV inhibitor by targeting the HIV-1 envelope glycoprotein gp120. This compound has been shown to release chemokines and protect against neuronal death induced by gp120. It is a valuable reagent for research into infectious diseases and neurological disorders, particularly AIDS-related dementia. -
HIV Entry Inhibitor
T-peptide is an HIV entry inhibitor that functions as a Tuftsin analog, effectively targeting HIV infection. This compound is known to mitigate cellular immunosuppression and enhance survival rates in septic mouse models. Additionally, T-peptide demonstrates the ability to inhibit the growth of residual tumor cells following surgical resection, making it a valuable tool for oncological and infectious disease research applications. -
Bacterial Inhibitor
Bombinin-Like Peptide (BLP-1) is an antimicrobial peptide derived from Bombina species, primarily functioning as a bacterial inhibitor. This peptide exhibits potent activity against a range of bacterial strains, making it a valuable tool for research in antimicrobial resistance and the development of new therapeutic agents. Its unique mechanism and efficacy position it as an important candidate for studies focused on infection control and peptide-based drug design. -
Cell-penetrating Peptide/Proteasome Inhibitor
Octaarginine is a cell-penetrating peptide and potent proteasome inhibitor. It exhibits mixed-type inhibition against the chymotrypsin-like, caspase-like, and trypsin-like activities of the 20S proteasome while displaying reduced efficacy against the 26S proteasome. This compound facilitates the accumulation of ubiquitin-conjugated proteins and promotes HSPG-dependent cellular internalization through macropinocytosis, thereby enhancing the uptake of liposomal cargo and gene delivery. Octaarginine is valuable for research related to cervix carcinoma, collagen antibody-induced arthritis, and bacterial infections. -
Bacterial Peptide Deformylase Inhibitor
Lanopepden camsylate is a high-affinity inhibitor of bacterial peptide deformylase, an enzyme critical for protein maturation in bacteria. This compound exhibits potent activity against bacterial infections by disrupting essential protein processing. Lanopepden camsylate is primarily utilized in research applications focused on the development of new antibacterial agents and the study of bacterial pathogenicity. -
CXCR4 Inhibitor
Peptide R is a cyclic peptide that functions as a specific antagonist of the CXCR4 receptor. It demonstrates significant efficacy in remodeling tumor stroma, making it a valuable tool for tumor research. Its ability to modulate the tumor microenvironment highlights its potential applications in cancer therapy and investigation into tumor progression mechanisms. -
α1 Adrenergic Receptor Inhibitor
Conopeptide rho-TIA is a peptide originating from the venom of the predatory sea snail Conus tulipa, serving as a highly selective noncompetitive inhibitor of the human α1B-adrenergic receptor. It also acts as a competitive inhibitor for both the α1A- and α1D-adrenergic receptors. By selectively binding to these receptor subtypes, conopeptide rho-TIA offers valuable insights for the development of novel, subtype-selective α1-adrenergic receptor therapies. Its unique mechanism of action makes it a potent tool for cardiovascular and pharmacological research. -
Dynamin Inhibitor
DynaMin inhibitory peptide, myristoylated is a specific inhibitor of dynamin, targeting the interaction between dynamin and amphiphysin. This membrane-permeant peptide effectively disrupts endocytosis processes, making it valuable for studying vesicle trafficking and membrane dynamics in various cellular contexts. Its ability to inhibit endocytic pathways allows for investigations into related cellular mechanisms and potential therapeutic applications in modulating cellular uptake processes. -
Drp1 Inhibitor
Drp1 peptide inhibitor P110 is a selective inhibitor of Dynamin-related protein 1 (Drp1), targeting mitochondrial dynamics. This compound exhibits neuroprotective effects by inhibiting Drp1 activation, preventing MPTP-induced mitochondrial translocation, and mitigating dopaminergic neuron loss along with associated behavioral deficits. Research applications include studies on Alzheimer's disease, as well as models of Huntington's disease, cerebral ischemic injury, and myocardial infarction, where P110 has demonstrated the ability to reduce mitochondrial damage and alleviate organ injury. -
Fibrinogen Binding Inhibitor Peptide
Fibrinogen Binding Inhibitor Peptide is a dodecapeptide derived from the carboxy-terminal sequence of the fibrinogen γ-chain (γ400-411). It specifically targets the binding site for activated glycoprotein (GP) IIb/IIIa, playing a crucial role in inhibiting fibrinogen interactions. This peptide is valuable for research applications focused on thrombosis, platelet aggregation, and cardiovascular disease mechanisms. -
Inhibitory Peptide
Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) functions as an inhibitory peptide targeting the α5β1 integrin. This synthetic ligand effectively competes with invasin for binding to the α5β1 integrin on Caco-2 cells, thereby disrupting cell adhesion and signaling processes. Its application is significant in studying integrin-related interactions and cellular behaviors, making it a valuable tool in cancer and cell biology research. -
MARCKS Inhibitor
MANS peptide is an inhibitor of myristoylated alanine-rich C kinase substrate (MARCKS), which functions by competing with MARCKS for membrane binding in cellular environments. This competitive inhibition effectively reduces the stimulation of mucin secretion and can impede processes related to tumor metastasis. MANS peptide is valuable for research investigating cellular signaling pathways and the role of MARCKS in cancer progression. -
smMLCK Inhibitor
smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK) that functions by mimicking the substrate and competitively inhibiting substrate binding. This mechanism disrupts kinase activity, preventing phosphorylation of the myosin light chain and subsequently inhibiting muscle contraction. It is a valuable tool for studying smooth muscle function and exploring therapeutic strategies for related disorders. -
Tyrosinase Inhibitor
Decapeptide-12 is a selective inhibitor of tyrosinase, exhibiting a Kd of 61.1 μM and acting as a competitive inhibitor with an IC50 of 40 μM against mushroom tyrosinase. This decapeptide enhances the transcription of SIRT and effectively reduces melanin content in melanocytes. Decapeptide-12 is valuable for research involving melanogenesis, cellular senescence, and inflammation. -
Angiogenesis Peptide Inhibitor
ALM-201 is a peptide antagonist of angiogenesis that specifically targets microtubules. It demonstrates significant biological activity by inhibiting cell migration, tubule formation, and microvessel development. ALM-201 is suitable for research applications focused on cancer biology and the mechanisms underlying tumor vascularization. -
Inhibitor Of The Binding Of DQ8 Peptide To MHC Class II Molecule
D-α-Methyl DOPA is an inhibitor of the binding of DQ8 peptide to MHC class II molecules. By occupying a pocket in the DQ8 peptide binding groove, D-α-Methyl DOPA disrupts the presentation of DQ8 peptides to CD4+ T cells. This inhibition may play a role in modulating the immune response, potentially slowing the development or progression of type 1 diabetes and celiac disease. This compound is valuable in immunological research focused on T cell activation and autoimmune disease mechanisms. -
SPSB2-iNOS Inhibitor
SPSB2-iNOS inhibitory cyclic peptide-1 is a potent inhibitor targeting the interaction between SPSB2 and inducible nitric oxide synthase (iNOS), exhibiting a binding affinity (KD) of 4.4 nM. This cyclic peptide demonstrates resistance to proteolytic degradation by pepsin, trypsin, and α-chymotrypsin, ensuring stability in biological environments. Additionally, it maintains stability in human plasma and oxidative conditions, making it a valuable tool for studying iNOS-related pathways in inflammation and other biological processes. -
SPSB2-iNOS Inhibitor
SPSB2-iNOS inhibitory cyclic peptide-2 is a selective inhibitor of the interaction between SPSB2 and inducible nitric oxide synthase (iNOS), exhibiting a binding affinity with a KD of 21 nM. This cyclic peptide is both reduction-resistant and oxidatively stable, making it suitable for various biological assays. Its ability to inhibit SPSB2-iNOS interactions positions it as a valuable tool in research focused on nitric oxide signaling and related pathophysiological processes. -
SPSB2-iNOS Inhibitor
SPSB2-iNOS inhibitory cyclic peptide-3 is a selective inhibitor targeting the interaction between SPSB2 and inducible nitric oxide synthase (iNOS). This compound binds to the SPSB2 site on iNOS with a dissociation constant (KD) of 7 nM. It demonstrates significant biological activity in modulating nitric oxide production and has potential applications in studies related to inflammation and oxidative stress. -
FOXP3 Inhibitor
Peptide P60 is a potent FOXP3 inhibitor that disrupts the nuclear translocation of FOXP3, thereby decreasing its regulatory effects on NF-κB and NFAT signaling pathways. This action inhibits the immunosuppressive capabilities of regulatory T cells, facilitating the proliferation and activation of effector T cells. Experimental studies have shown that Peptide P60 can induce lymphoproliferative autoimmune syndrome in neonatal ICR mice and diminish the population of CD4+CD25+Foxp3+ T cells in the spleen. Additionally, it enhances the efficacy of peptide vaccines and recombinant adenovirus-based vaccines, making it valuable for research in tumor immunology, viral infections, and autoimmune conditions. -
Ras Inhibitor
Ras Inhibitory Peptide (VPPPVPPRRR) is a specific inhibitor of Ras proteins, known for its antitumor activity. This peptide disrupts Ras signaling pathways, which are critical for cell growth and proliferation, making it a valuable tool in cancer research. Its ability to modulate Ras activity allows for the investigation of therapeutic strategies targeting oncogenic Ras mutations. -
BCL6 Inhibitor
SMRT peptide is a BCL6 inhibitor that functions by binding to the BTB domain of BCL6, thereby enhancing its transcriptional repression activity. This compound serves as a valuable tool for studying protein-protein interactions related to BCL6 function in various biological processes. Research applications include investigations into the role of BCL6 in cancer and other diseases where transcriptional regulation is critical. -
Opioid Receptor Inhibitor
Neuropeptide AF (human) is an endogenous peptide that acts as an opioid receptor inhibitor. This neuropeptide plays a critical role in modulating pain and stress responses, making it a valuable tool for studies focused on opioid signaling pathways. Research applications include investigations into pain management, addiction, and the physiological effects of endogenous opioid peptides. -
GluR6/PSD-95 Inhibitor
PDZ1 Domain Inhibitor Peptide is a cyclic peptide designed to specifically target the PDZ1 domains of postsynaptic density protein 95 (PSD-95). By disrupting the interaction between GluR6 and PSD-95, this inhibitor effectively competes with the C terminus of GluR6 for binding to the PDZ1 domain. Its unique β-Ala lactam side chain linker enhances its efficacy in studies related to synaptic signaling and glutamate receptor regulation. This reagent is ideal for research applications focusing on neuronal communication and synaptic plasticity. -
Peptide Inhibitor
p-fin4 is a peptide inhibitor targeting the interaction between STEP phosphatase and the GluA2 subunit of the AMPA receptor, with a Ki of 0.4 μM. This compound has demonstrated the ability to restore memory deficits and exhibits anxiolytic and antidepressant effects in a scopolamine-induced rat model. p-fin4 represents a potential lead for the development of innovative cognitive enhancers and behavioral modulators, highlighting its significance in neurological research. -
Na+/K+ ATPase Inhibitor
Transdermal Peptide Disulfide is a synthetic 11-amino acid peptide that serves as an inhibitor of the Na+/K+-ATPase by binding to the beta-subunit (ATP1B1) and specifically interacting with its C-terminus. This compound enhances the transdermal delivery of various macromolecules, making it a valuable tool in drug formulation and transdermal research applications. Its ability to facilitate the transport of biologically relevant molecules may have significant implications for improving therapeutic delivery in clinical settings. -
NF-κB Inhibitor
NBD peptide is a selective inhibitor of the NF-κB signaling pathway, acting by disrupting the interaction between NEMO and the IKK complex. This inhibition leads to reduced production of pro-inflammatory cytokines, showcasing its anti-inflammatory properties. Additionally, NBD peptide demonstrates immunosuppressive effects through modulation of immune cell activity. The incorporation of the cell-penetrating HIV-TAT peptide enhances its cellular uptake, facilitating its application in various research contexts.
